<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The JAK2 V617F mutation has been noted in the cases of <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, and primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>This mutation occurs less frequently in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and other <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e>, such as <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>); myelodysplatic syndrome/myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo>, unclassifiable (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN-U); and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts with <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patients diagnosed with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> other than MPN who visited Seoul St Mary's Hospital from January 2007 to February 2010 were selected </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 43 patients were enrolled in this study: 12 MDS, 9 MDS/MPN-U, 7 RARS-T, and 15 AML patients </plain></SENT>
<SENT sid="4" pm="."><plain>The diseases were diagnosed according to the 2008 WHO classification criteria </plain></SENT>
<SENT sid="5" pm="."><plain>Data obtained from JAK2 V617F mutation analysis and cytogenetic study as well as complete blood count and clinical data were analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Of the 43 patients, 6 (13.9%) harbored the JAK2 V617F mutation </plain></SENT>
<SENT sid="7" pm="."><plain>The incidence of the JAK2 V617F mutation in each patient group was as follows: 8.3% (1/12), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; 22.2% (2/9), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN-U; 14.3% (1/7), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T; and 13.3%, (2/15) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The platelet count was higher than 450Ã—10(9)/L in 3 of the 6 patients (50%) harboring the JAK2 V617F mutation, and it was in the <z:mpath ids='MPATH_458'>normal</z:mpath> range in the remaining 3 patients </plain></SENT>
<SENT sid="9" pm="."><plain>Among the 6 patients, 1 MDS and 1 MDS/MPN-U patients had the 46,XX,del(20)(q11.2) karyotype </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The JAK2 V617F mutation is associated with an <z:hpo ids='HP_0001894'>increased platelet count</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN-U, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="11" pm="."><plain>Cytogenetic abnormalities of del(20)(q11.2) occurred in 1/3 of patients with the JAK2 V617F mutation but further studies are required to confirm this association </plain></SENT>
</text></document>